PROPEL
A Holistic Approach for Achondroplasia Research
About the PROPEL Study
(for children <3 years old)
The PROPEL program is studying the effects of infigratinib in children and adolescents who are over 3 but under 18 years of age. Now, BridgeBio is studying younger age groups in the PROPEL Infant & Toddler study, which is investigating the effects of the study drug in children under 3 years of age1.
The Infant and Toddler Study is the only recruiting trial for the PROPEL program. All other studies have completed enrollment.
PROPEL Infant & Toddler Study Design
The PROPEL Infant & Toddler study is a phase 2/2b study to evaluate the safety and efficacy of infigratinib in children with ACH under 3 years of age. The study consists of four portions, each building on the last.
Infigratinib is an investigational medication that has not been approved by the US or any regulatory agency. Its safety and efficacy are unknown.
For additional information about the PROPEL Infant & Toddler study, including eligibility requirements and study locations, visit https://clinicaltrials.gov/study/NCT07169279.
About the PROPEL Clinical Program
(for children 3 to <18 years old)
The PROPEL clinical program is studying a wide range of outcomes related to growth, medical challenges, and quality of life in children and adolescents with achondroplasia2.
PROPEL Program Study Design
PROPEL is an observational study, in which no treatment is given. PROPEL 2 and PROPEL 3 are interventional studies, in which participants receive infigratinib and/or placebo2–4.
A placebo is a treatment with no active properties, such as a sugar pill. Participants from PROPEL 2, PROPEL 3, and PROPEL Infant & Toddler will have the opportunity to enroll in PROPEL OLE, an open-label extension study, where they may continue to receive the investigational drug until their growth is complete2–5.